Monaco Asset Management SAM Has $908,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Monaco Asset Management SAM increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 250.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,149,708 shares of the biopharmaceutical company's stock after acquiring an additional 822,037 shares during the period. Monaco Asset Management SAM owned approximately 1.00% of Fate Therapeutics worth $908,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of FATE. American Century Companies Inc. grew its holdings in shares of Fate Therapeutics by 6.6% during the 4th quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company's stock worth $326,000 after purchasing an additional 12,295 shares during the period. LPL Financial LLC acquired a new position in Fate Therapeutics during the 4th quarter valued at about $121,000. Franklin Resources Inc. increased its stake in Fate Therapeutics by 9.6% during the 4th quarter. Franklin Resources Inc. now owns 165,353 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 14,532 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Fate Therapeutics by 56.3% in the fourth quarter. Wells Fargo & Company MN now owns 92,395 shares of the biopharmaceutical company's stock valued at $152,000 after buying an additional 33,284 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Fate Therapeutics by 42.9% in the fourth quarter. Russell Investments Group Ltd. now owns 89,823 shares of the biopharmaceutical company's stock worth $148,000 after buying an additional 26,953 shares during the last quarter. 97.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on FATE shares. Wall Street Zen lowered Fate Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 28th. Needham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, June 12th. Barclays lowered their target price on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Finally, Robert W. Baird dropped their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating for the company in a research report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $3.83.

Fate Therapeutics Stock Performance

NASDAQ:FATE traded down $0.03 during trading hours on Friday, hitting $1.07. The stock had a trading volume of 767,002 shares, compared to its average volume of 2,084,980. The company has a market cap of $122.62 million, a price-to-earnings ratio of -0.72 and a beta of 2.18. Fate Therapeutics, Inc. has a one year low of $0.66 and a one year high of $4.66. The business's 50 day moving average is $1.23 and its 200-day moving average is $1.16.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.07. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.18 million. Fate Therapeutics had a negative return on equity of 47.17% and a negative net margin of 1,318.93%. On average, sell-side analysts anticipate that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.